Ipsen Positive On Palovarotene Despite Troubled Past

Filings For FOP In Early 2021

Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.

folders
Filings nearly ready for Ipsen's ultra rare bone disease drug • Source: Shutterstock

Ipsen SA CEO David Loew has put up a stout defence of the company's ultra-rare bone disease therapy palovarotene which, despite a pretty precarious history, is set to be filed with regulators early next year.

The French drugmaker got hold of palovarotene for fibrodysplasia ossificans progressive (FOP) in February 2019 through the acquisition of Canadian...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Rare Diseases

More from Scrip